

CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF

PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

Available online at: http://www.iajps.com

Research Article

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF BUPRENORPHINE AND NALOXONE IN BULK AND PHARMACEUTICAL DOSAGE FORM

S. Bhavana *, Dr.G.Vijaya Kumar¹,B.Sravanthi²

¹Department Of Pharmaceutical Analysis, KGR Institute Of Technology & Management Rampally, Secunderabad, Telangana 501301

Abstract:

A novel, precise, accurate, rapid and cost effective isocratic reverse phase high performance liquid chromatographic (RP-HPLC) method was developed, optimized and validated for the estimation of Buprenorphine and Naloxone in bulk and pharmaceutical dosage forms. The drugs were estimated using Phenomenex Gemini C18 (4.6mm×150mm, 5.0 µm) particle size column. A mobile phase composed of tri ethylamine buffer and methanol in proportion of 32:68 v/v, at a flow rate of 1.0 ml/min was used for the separation. Detection was carried out at 248 nm. The linearity range obtained was 30-70 µg/ml for Buprenorphine and 10-50 µg/ml for Naloxone with retention times (Rt) of 3.297 min and 5.405 min for Buprenorphine and Naloxone respectively. The correlation coefficient values were found to be 0.999 & 0.999. Precession studies showed % RSD values less than 2 % for both the drugs in all the selected concentrations. The percentage recoveries of Buprenorphine and Naloxone were found to be 100.1873% for Buprenorphine and 100.748% for Naloxone respectively. The assay results of Buprenorphine and Naloxone were found to be 99.82%. The limit of detection (LOD) and limit of quantification (LOQ) were 2.6µg/ml and 7.8µg/ml for Buprenorphine and 3.4µg/ml 10.2µg/ml for Naloxone respectively. The proposed method was validated as per the International Conference on Harmonization (ICH) guidelines. The proposed validated method was successfully used for the quantitative analysis of commercially available dosage form.

Keywords: Buprenorphine and Naloxone, RP-HPLC, ICH Guidelines, Validation.

Corresponding author:

S Bhavana,

Department of Pharmaceutical Analysis, KGR Institute Of Technology & Management Rampally, Secunderabad, Telangana. Email Id- sbhavana0719@gmail.com



Please cite this article in press S Bhavana et al Development And Validation Of Rp-Hplc Method For The Simultaneous Estimation Of Buprenorphine And Naloxone In Bulk And Pharmaceutical Dosage Form, Indo Am. J. P. Sci, 2023; 10 (12).

INTRODUCTION:

Analytical chemistry [1]

Analytical chemistry is a scientific discipline used to study the chemical composition, structure and behaviour of matter. The purposes of chemical analysis are together and interpret chemical information that will be of value to society in a wide range of contexts. Quality control in manufacturing industries, the monitoring of clinical and environmental samples, the assaying of geological specimens, and the support of fundamental and applied research are the principal applications. Analytical chemistry involves the application of a range of techniques and methodologies to obtain and assess qualitative, quantitative and structural information on the nature of matter.

Qualitative analysis is the identification of elements, species and/or compounds present in sample.

Quantitative analysis is the determination of the absolute or relative amounts of elements, species or compounds present in sample.

Analytical techniques There are numerous chemical or physico-chemical processes that can be used to provide analytical information. The processes are related to a wide range of atomic and molecular properties and phenomena that enable elements and compounds to be detected and/or quantitatively measured under controlled conditions. underlying processes define the various analytical techniques. The more important of these are listed in Table.No.1 together with their suitability for qualitative, quantitative or structural analysis and the levels of analyte(s) in a sample that can be measured. molecular spectrometry Atomic, chromatography, which together comprise the largest and most widely used groups of techniques, can be further subdivided according to their physicochemical basis. Spectrometric techniques may involve either the emission or absorption of electromagnetic radiation over a very wide range of energies, and can provide qualitative, quantitative and structural information for analytes from major components of a sample down to ultra-trace levels. Chromatographic techniques provide the means of separating the components of mixtures and simultaneous qualitative and quantitative analysis, as required. The linking of chromatographic and spectrometric techniques, called hyphenation, provides a powerful means of separating and identifying unknown compounds.

Analytical methods

An analytical method consists of a detailed, stepwise list of instructions to be followed in the qualitative, quantitative or structural analysis of a sample for one

or more analytes and using a specified technique. It will include a summary and lists of chemicals and reagents to be used, laboratory apparatus and glassware, and appropriate instrumentation. The quality and sources of chemicals, including solvents, and the required performance characteristics of instruments will also be specified as will the procedure for obtaining a representative sample of the material to be analyzed. This is of crucial importance in obtaining meaningful results. The preparation or pre-treatment of the sample will be followed by any necessary standardization of reagents and/or calibration of instruments under specified conditions. Qualitative tests for the analyte(s) or quantitative measurements under the same conditions as those used for standards complete the practical part of the method. The remaining steps will be concerned with data processing, computational methods quantitative analysis and the formatting of the analytical report. The statistical assessment of quantitative data is vital in establishing the reliability and value of the data, and the use of various statistical parameters and tests is widespread. Many standard analytical methods have been published as papers in analytical journals and other scientific literature, and in textbook form. Collections by trades associations representing, for example, the cosmetics, food, iron and steel, pharmaceutical, polymer plastics and paint, and water industries are available standards organizations and statutory authorities, instrument manufacturer's applications notes, the Royal Society of Chemistry and the US Environmental Protection Agency are also valuable sources of standard methods. Often, laboratories will develop their own in-house methods or adapt existing ones for specific purposes.

Method development forms a significant part of the work of most analytical laboratories, and *method validation and* periodic revalidation is a necessity. Selection of the most appropriate analytical method should take into account the following factors:

- The purpose of the analysis, the required time scale and any cost constraints;
- The level of Analyte(s) expected and the detection limit required;
- The nature of the sample, the amount available and the necessary sample preparation procedure;
- The accuracy required for a quantitative analysis;
- The availability of reference materials, standards, chemicals and solvents, instrumentation and any special facilities;
- Possible interference with the detection or quantitative measurement of the analyte(s) and

the possible need for sample clean-up to avoid matrix interference;

- The degree of selectivity available methods may be selective for a small number of analytes or specific for only one.
- Quality control and safety factors.

MATERIALS AND METHODS:

Buprenorphine -Sura labs, Naloxone-Sura labs, Water and Methanol for HPLC-LICHROSOLV (MERCK), Acetonitrile for HPLC -Merck

Hplc method development:

Trails:

Preparation of standard solution:

Accurately weigh and transfer 10 mg of Buprenorphine and Naloxone working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol.

Further pipette 0.1ml of the above Buprenorphine and 0.3ml of the Naloxone stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines.

Optimized chromatographic conditions:

Instrument used: Waters HPLC with auto sampler and PDA Detector 996 model.

Temperature : 35°C

Column : Phenomenex Luna C18 (4.6×250mm, 5µm) particle size

Buffer : Dissolve 6.8043 of potassium dihydrogen phosphate in 1000 ml HPLC water and adjust the pH 4.6 with diluted orthophosphoric acid. Filter and sonicate the solution by vacuum filtration and ultra sonication.

pH : 4.6

Mobile phase : Acetonitrile: Phosphate Buffer (45:55 v/v)

Flow rate : 1ml/min Wavelength : 245 nm

Injection volume: 10 µl

Run time : 7 min

Validation

Preparation of mobile phase:

Preparation of mobile phase:

Accurately measured 450 ml (45%) of Methanol, 550 ml of Phosphate buffer (55%) were mixed and degassed in digital ultrasonicater for 15 minutes and then filtered through $0.45~\mu$ filter under vacuum filtration.

Diluent Preparation:

The Mobile phase was used as the diluent.

RESULTS AND DISCUSSION:

Optimized Chromatogram (Standard)

Column : Phenomenex Gemini C18 (4.6mm×150mm, 5.0 μm) particle size

Column temperature : 38°C Wavelength : 248nm

Mobile phase ratio : Methanol: TEA buffer pH 4.8 (32:68v/v)

Flow rate : 1ml/min

Injection volume : 20µl

Run time : 7minutes




Figure-: Optimized Chromatogram (Standard)

Table No.18: Optimized Chromatogram (Standard)

| S.No | Name | RT | Area | Height | USP Tailing | USP Plate Count | USP Resolution |
|------|---------------|-------|--------|--------|-------------|-----------------|-------------------|
| 1 | Buprenorphine | 3.297 | 859857 | 42568 | 1.25 | 7897 | |
| 2 | Naloxone | 5.405 | 5699 | 3653 | 1.37 | 6583 | 6.9 |

Optimized Chromatogram (Sample)




Figure-: Optimized Chromatogram (Sample)

Table No. 19: Optimized Chromatogram (Sample)

| S.No | Name | RT | Area | Height | USP Tailing | USP Plate Count | USP Resolution |
|------|---------------|-------|--------|--------|-------------|-----------------|----------------|
| 1 | Buprenorphine | 3.222 | 865899 | 43658 | 1.27 | 7986 | |
| 2 | Naloxone | 5.453 | 5787 | 3786 | 1.39 | 6658 | 7.1 |

Acceptance Criteria:

• Resolution between two drugs must be not less than 2.

- Theoretical plates must be not less than 2000.
- Tailing factor must be not less than 0.9 and not more than 2.
- It was found from above data that all the system suitability parameters for developed method were within the limit.

Assay (Standard):

Table-: Peak results for assay standard

Buprenorphine

| S.No. | Name | RT | Area | Height | USP Tailing | USP Plate Count |
|-------|---------------|-------|--------|--------|-------------|------------------------|
| 1 | Buprenorphine | 3.211 | 859786 | 42599 | 1.26 | 7857 |
| 2 | Buprenorphine | 3.222 | 859864 | 42895 | 1.25 | 7858 |
| 3 | Buprenorphine | 3.254 | 857848 | 42579 | 1.26 | 7868 |

Naloxone

| S.No | Name | RT | Area | Height | USP Tailing | USP Plate Count | Resolution |
|------|----------|-------|------|--------|-------------|------------------------|------------|
| 1 | Naloxone | 5.414 | 5698 | 3686 | 1.36 | 6599 | 6.8 |
| 2 | Naloxone | 5.453 | 5686 | 3658 | 1.37 | 6538 | 6.7 |
| 3 | Naloxone | 5.424 | 5688 | 3647 | 1.36 | 6583 | 7.1 |

Assay (Sample):


Table-: Peak results for Assay sample

Buprenorphine

| S.No | Name | RT | Area | Height | USP Tailing | USP Plate Count |
|------|---------------|-------|--------|--------|-------------|------------------------|
| 1 | Buprenorphine | 3.297 | 865986 | 43658 | 1.26 | 7986 |
| 2 | Buprenorphine | 3.294 | 865799 | 43876 | 1.26 | 7924 |
| 3 | Buprenorphine | 3.295 | 865457 | 43657 | 1.27 | 7948 |

Naloxone

| 1100000 | | | | | | | |
|---------|----------|-------|------|--------|-------------|------------------------|------------|
| S.No | Name | RT | Area | Height | USP Tailing | USP Plate Count | Resolution |
| 1 | Naloxone | 5.435 | 5788 | 3658 | 1.37 | 6658 | 6.9 |
| 2 | Naloxone | 5.417 | 5797 | 3683 | 1.38 | 6698 | 7.0 |
| 3 | Naloxone | 5.434 | 5748 | 3694 | 1.38 | 6647 | 6.9 |



^{= 99.89%}


The % purity of Buprenorphine and Naloxone in pharmaceutical dosage form was found to be 99.82%.

Linearity

Chromatographic data for linearity study:

Buprenorphine:

| Concentration µg/ml | Average Peak Area |
|------------------------|----------------------|
| 30 | 545893 |
| 40 | 725986 |
| 50 | 897857 |
| 60 | 1068593 |
| 70 | 1245698 |



Naloxone:

| Concentration | Average |
|---------------|-----------|
| μg/ml | Peak Area |
| 10 | 2039 |
| 20 | 3858 |
| 30 | 5697 |
| 40 | 7488 |
| 50 | 9217 |




Fig: Chromatogram showing linearity level

Repeatability:

Table-: Results of Repeatability for Buprenorphine:

| S. No. | Peak name | Retention time | Area(µV*sec) | Height (µV) | USP Plate Count | USP Tailing |
|---------|---------------|----------------|--------------|-------------|--------------------|----------------|
| 1 | Buprenorphine | 3.213 | 859857 | 42658 | 7858 | 1.24 |
| 2 | Buprenorphine | 3.253 | 857986 | 42597 | 7867 | 1.24 |
| 3 | Buprenorphine | 3.297 | 856983 | 42586 | 7845 | 1.25 |
| 4 | Buprenorphine | 3.215 | 856986 | 42568 | 7818 | 1.25 |
| 5 | Buprenorphine | 3.254 | 859877 | 42893 | 7855 | 1.24 |
| Mean | | | 858338 | | | |
| Std.dev | | | 1454.222 | | | |
| %RSD | | | 0.169423 | | | |

Acceptance Criteria:

- %RSD for sample should be NMT 2
- The %RSD for the standard solution is below 1, which is within the limits hence method is precise.

Table: Results of Repeatability for Naloxone:

| | | Table . Results (| or responding r | 01 1 (4410)10110 | | |
|---------|-----------|-------------------|-----------------|------------------|--------------------|----------------|
| S. No. | Peak Name | Retention time | Area(µV*sec) | Height (µV) | USP Plate Count | USP Tailing |
| 1 | Naloxone | 5.441 | 5698 | 3658 | 6593 | 1.36 |
| 2 | Naloxone | 5.442 | 5687 | 3649 | 6538 | 1.36 |
| 3 | Naloxone | 5.409 | 5688 | 3693 | 6585 | 1.37 |
| 4 | Naloxone | 5.520 | 5638 | 3649 | 6578 | 1.36 |
| 5 | Naloxone | 5.424 | 5687 | 3688 | 6542 | 1.36 |
| Mean | · | | 5679.6 | | | |
| Std.dev | · | | 23.71287 | | | |
| %RSD | · | | 0.417509 | | | |

Intermediate precision: Buprenorphine

| S.No. | Peak Name | RT | Area (μV*sec) | Height (µV) | USP Plate count | USP Tailing |
|-----------|---------------|-------|------------------|-------------|-----------------|-------------|
| 1 | Buprenorphine | 3.211 | 868957 | 43658 | 7986 | 1.26 |
| 2 | Buprenorphine | 3.211 | 869858 | 43986 | 7953 | 1.27 |
| 3 | Buprenorphine | 3.210 | 865984 | 43878 | 7945 | 1.26 |
| 4 | Buprenorphine | 3.212 | 866588 | 43866 | 7962 | 1.27 |
| 5 | Buprenorphine | 3.211 | 864257 | 43874 | 7963 | 1.26 |
| 6 | Buprenorphine | 3.297 | 868973 | 43563 | 7943 | 1.26 |
| Mean | | | 867435.5 | | | |
| Std. Dev. | | | 2167.095 | | | |
| % RSD | | | 0.249828 | | | |

Acceptance Criteria:

• %RSD of six different sample solutions should not more than 2.

Table: Results of Intermediate precision day1 for Naloxone

| S.No. | Peak Name | RT | Area (μV*sec) | Height (µV) | USP Plate count | USP Tailing |
|-----------|-----------|-------|------------------|-------------|-----------------|-------------|
| 1 | Naloxone | 5.411 | 5785 | 3789 | 6659 | 1.37 |
| 2 | Naloxone | 5.410 | 5798 | 3758 | 6625 | 1.38 |
| 3 | Naloxone | 5.420 | 5766 | 3746 | 6649 | 1.38 |
| 4 | Naloxone | 5.423 | 5746 | 3795 | 6675 | 1.37 |
| 5 | Naloxone | 5.419 | 5782 | 3761 | 6653 | 1.38 |
| 6 | Naloxone | 5.409 | 5786 | 3752 | 6627 | 1.37 |
| Mean | | | 5777.167 | | | |
| Std. Dev. | | | 18.40018 | | | |
| % RSD | | | 0.318498 | | | |

Acceptance Criteria:

• %RSD of six different sample solutions should not more than 2.

Table-: Results of Intermediate precision Day 2 for Buprenorphine

| S.No. | Peak Name | RT | Area (μV*sec) | Height (μV) | USP Plate Count | USP Tailing |
|-----------|---------------|-------|------------------|-------------|--------------------|-------------|
| 1 | Buprenorphine | 3.211 | 845986 | 44586 | 8026 | 1.27 |
| 2 | Buprenorphine | 3.233 | 847894 | 44897 | 8068 | 1.28 |
| 3 | Buprenorphine | 3.244 | 848987 | 44759 | 8047 | 1.27 |
| 4 | Buprenorphine | 3.297 | 847858 | 44547 | 8093 | 1.28 |
| 5 | Buprenorphine | 3.297 | 845985 | 44866 | 8041 | 1.28 |
| 6 | Buprenorphine | 3.202 | 847899 | 44253 | 8077 | 1.27 |
| Mean | | | 847434.3 | | | |
| Std. Dev. | | | | | | |
| | | | 1201.345 | | | |
| % RSD | | | 0.141763 | | | |

Acceptance Criteria:

• %RSD of six different sample solutions should not more than 2.

Table: Results of Intermediate precision Day 2 for Naloxone

| S.No. | Peak Name | RT | Area (μV*sec) | Height (µV) | USP Plate Count | USPTailing |
|-----------|-----------|-------|------------------|-------------|-----------------|------------|
| 1 | Naloxone | 5.411 | 5899 | 3987 | 6853 | 1.39 |
| 2 | Naloxone | 5.410 | 5885 | 3956 | 6865 | 1.39 |
| 3 | Naloxone | 5.420 | 5864 | 3957 | 6828 | 1.40 |
| 4 | Naloxone | 5.405 | 5847 | 3946 | 6873 | 1.39 |
| 5 | Naloxone | 5.409 | 5898 | 3927 | 6828 | 1.39 |
| 6 | Naloxone | 5.463 | 5875 | 3963 | 6826 | 1.40 |
| Mean | | | 5876.667 | | | |
| Std. Dev. | | | 20.39281 | | | |
| % RSD | | | 0.347013 | | | |

Acceptance Criteria:

• %RSD of six different sample solutions should not more than 2.

Accuracy:

Table-: The accuracy results for Buprenorphine

| %Concentration (at specification Level) | Area | Amount Added (ppm) | Amount Found (ppm) | % Recovery | Mean Recovery |
|---|----------|--------------------------|--------------------------|------------|------------------|
| 50% | 451145.3 | 25 | 24.997 | 99.993% | |
| 100% | 897249.3 | 50 | 50.103 | 100.209% | 100.1869% |
| 150% | 1344563 | 75 | 75.279 | 100.363% | |

Table: The accuracy results for Naloxone

| %Concentration (at specification Level) | Area | Amount Added (ppm) | Amount Found (ppm) | % Recovery | Mean Recovery |
|---|----------|--------------------------|--------------------------|------------|------------------|
| 50% | 2896 | 15 | 15.083 | 100.561% | |
| 100% | 5686.333 | 30 | 30.284 | 100.942% | 100.749% |
| 150% | 8448 | 45 | 45.336 | 100.745% | |

Robustness

Table-: Results for Robustness Results for Robustness - Buprenorphine

| Parameter used for sample analysis | Peak Area | Retention Time | Theoretical plates | Tailing factor |
|--|-----------|----------------|--------------------|----------------|
| Actual Flow rate of 1.0mL/min | 859857 | 3.297 | 7895 | 1.24 |
| Less Flow rate of 0.9mL/min | 915848 | 3.639 | 7252 | 1.20 |
| More Flow rate of 1.1mL/min | 842563 | 2.859 | 7416 | 1.21 |
| Less organic phase (about 5 % decrease in organic phase) | 825499 | 3.460 | 7364 | 1.23 |
| More organic phase (about 5 % Increase in organic phase) | 814577 | 3.022 | 7259 | 1.22 |

Table: Results for Robustness- Naloxone

| Parameter used for sample analysis | Peak Area | Retention Time | Theoretical plates | Tailing factor |
|--|-----------|----------------|--------------------|----------------|
| Actual Flow rate of 1.1mL/min | 5699 | 5.405 | 6583 | 1.36 |
| Less Flow rate of 0.9mL/min | 6453 | 6.250 | 6786 | 1.32 |
| More Flow rate of 0.8mL/min | 5255 | 4.863 | 6364 | 1.34 |
| Less organic phase (about 5 % decrease in organic phase) | 5488 | 6.196 | 6253 | 1.38 |
| More organic phase (about 5 % Increase in organic phase) | 5367 | 5.010 | 6297 | 1.33 |

Acceptance Criteria:

The tailing factor should be less than 2.0 and the number of theoretical plates (N) should be more than 2000.

CONCLUSION:

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Buprenorphine and Naloxone was done by RP-HPLC.

The TEA buffer was p^H 4.8 and the mobile phase was optimized with consists of Methanol: TEA buffer mixed in the ratio of 32:68 % v/v.

A Phenomenex Gemini C18 ($4.6\text{mm} \times 150\text{mm}$, 5.0 μm) particle size or equivalent chemically bonded to porous silica particles was used as stationary phase.

The solutions were chromatographed at a constant flow rate of 1.0 ml/min. The linearity range of Buprenorphine and Naloxone were found to be from $30\text{-}70\mu\text{g/ml}$, $10\text{-}50\mu\text{g/ml}$ respectively. Linear regression coefficient was not more than 0.999, 0.999.

The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage

recovery varies from 98-102% of Buprenorphine and Naloxone. LOD and LOQ were found to be within limit

The results obtained on the validation parameters met ICH and USP requirements. It inferred the method found to be simple, accurate, precise and linear.

The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

Acknowledgement:

The Authors are thankful to the Management and Principal, Department of Pharmacy, KGR Institute Of Technology & Management Rampally, Secunderabad, Telangana, for extending support to carry out the research work. Finally, the authors express their gratitude to the Sura Labs, Dilsukhnagar, Hyderabad, for providing research equipment and facilities.

BIBLIOGRAPHY:

1. Gabor S. HPLC in pharmaceutical Analysis: Vol. I. 1st Ed. London: CRC Press; 1990:101-173.

- 2. Jeffery GH, Bassett J. Vogel's textbook of Quantitative Chemical Analysis. 5th Ed. New York: John Wiley & Sons Inc; 1991: 217-235.
- 3. Hobart HW, Merritt LL, John AD. Instrumental Methods of Analysis. 7th Ed. New Delhi: CBS Publishers; 1988: 580-610.
- 4. P.D. Sethi. HPLC: Quantitative analysis pharmaceutical formulations, CBS publishers and distributors, New Delhi (India), 2001, P.3-137.
- Michael E, Schartz IS, Krull. Analytical method development and validation. 2004, P. 25-46.
- 6. Sharma BK. Instrumental methods of chemical analysis, Introduction to analytical

- chemistry, 23th ed .Goel publishing house meerut, 2004,P12-23.
- H.H. Willard, L.L. Merritt, J.A. Dean, F.A. Settle. Instrumental methods of analysis, 7th edition, CBS publishers and distributors, New Delhi. 1986, P.518-521, 580-610.
- 8. John Adamovies, Chromatographic analysis of pharmaceutical, Marcel Dekker Inc. New York, 2nd ed, P.74, 5-15.
- 9. Gurdeep Chatwal, Sahm K. Anand. Instrumental methods of chemical analysis, 5th edition, Himalaya publishing house, New Delhi, 2002, P.1.1-1.8, 2.566-2.570
- 10. D. A. Skoog. J. Holler, T.A. Nieman. Principle of instrumental analysis, 5th edition, Saunders college publishing, 1998, P.778-787.